RC
ZNTL icon

RBF Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

RBF Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Sell
30,000
-20,000
-40% -$79.8K 0.01% 491
2026
Q1 		$117K Sell
50,000
-30,000
-38% -$77.5K 0.01% 473
2025
Q4 		$108K Hold
80,000
– – ﹤0.01% 534
2025
Q3 		$121K Hold
80,000
– – 0.01% 548
2025
Q2 		$92.8K Buy
+80,000
New +$106K ﹤0.01% 580

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RBF Capital's ZNTL Position: Q2 2026 in Review

RBF Capital reduced its Zentalis Pharmaceuticals (ZNTL) stake by 40% in Q2 2026, selling an estimated $79.8K and leaving 30,000 shares worth $146K. The position accounts for 0.01% of the portfolio, ranked #491.

RBF Capital first reported a position in ZNTL in Q2 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • RBF Capital held 30,000 shares of Zentalis Pharmaceuticals worth $146K as of Q2 2026.
  • RBF Capital sold 20,000 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $79.8K.
  • Zentalis Pharmaceuticals made up 0.01% of RBF Capital's portfolio in Q2 2026, its #491 holding.
  • RBF Capital first reported a position in Zentalis Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.